antimicrobials or to repurpose discontinued or shelved drugs to be used against resistant "superbugs". Antibiotic resistance develops in part because the antibiotics we use kill the bacteria. However, this creates
mechanisms, causing difficult-to-treat infections (1; 2; 3). Among the leading group of superbugs (ESKAPE) are Pseudomonas aeruginosa (PA) and Klebsiella pneumoniae (KP), that can rapidly gain resistances
mechanisms, causing difficult-to-treat infections (1; 2; 3). Among the leading group of superbugs (ESKAPE) are Pseudomonas aeruginosa (PA) and Klebsiella pneumoniae (KP), that can rapidly gain resistances
antifungals and anthelmintic. The microorganisms that develop antimicrobial resistance are sometimes referred to as 'superbugs'. As a result the medicines become ineffective and infections persist in the body increasing
preventing sepsis and aiding second degree burns healing even in extensive severity. However SUPERBUGS will be taken care by BACTERIOPHAGE in Future. Innovation is the hall mark of plastic surgeons
witnessed a dramatic drop in antibiotics efficacy in the last few decades due to superbugs emergence and dissemination. With an estimated 10 million deaths per year by 2050, the world
antibiotics without reporting of culture and sensitivity leads to development of these multidrug resistant superbugs in the world of microbi- ology and this creates problem for the treatment of ICUs
fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global
antfungals and anthlmintics. The microorganisms that develop antimicrobial resistance are sometimes referred to as 'superbugs'. As a result the medicines become inffective and infections persist in the body increasing
quick worldwide spread of multi-and container safe microscopic organisms (otherwise called "superbugs") that cause diseases that are not treatable with existing antimicrobial prescriptions like anti-microbials
capacity is additionally enlarged by steady development of new clones, making S. aureus a "superbug." Clinical utilization of methicillin has prompted the presence of methicillin-safe S. aureus (MRSA
fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global
fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global
fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). Strains often referred to as “nightmare superbugs” with highly elevated resistance to last-resort antibiotics have been reported all around the world
first-in-class novel chemical entity (NCE) that exhibits potent killing of pan-resistant superbugs such as E. coli (including ESBLs, NDM-1), S. aureus (including MRSA), K. pneumoniae (including
bacterial resistance against them, which create a new types of microorganism antibiotic assistance named superbugs. Antibiotic resistance is the ability of a bacterium or other micro-organisms to survive
affect the aquatic ecosystem, and may aid in development of antibiotic resistance in bacteria (‘superbugs’). Yamuna river originates from the Great Himalayan glaciers and passes through the national capital territory
resistance against them[1], which create a nuw types of microorganism antibiotic aesistance named superbugs. Antibiotic resistance is the ability of a bacterium or other micro-organisms to survive
resort treatments known as extended-spectrum cephalosporins (ESCs) is now eminent. The five riskiest superbugs are globally recognized as (1) the original one: Staphylococcus Aureus (MRSA), (2) the hospital lurkers
frequent cause of illness. At the same time the waged war against antibiotic resistant superbugs continues, where patient cases are becoming more prevalent and medically difficult to treat, as pathogens
understanding and standardized approach evaluated in clinical trials still needed. Thousands succumb to untreatable superbug infections on a daily basis. Meantime 33,000 people die every year due to infections
understanding and standardized approach evaluated in clinical trials still needed. Thousands succumb to untreatable superbug infections on a daily basis. Meantime 33,000 people die every year due to infections
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.